Catalyst Pharmaceuticals, Inc. (CPRX) is a Healthcare stock trading at $31.38 (as of 2026-06-18), with a market capitalization of $3.82B and a trailing P/E of 18.1. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for rare neuromuscular and neurological diseases in the United States. Its products include Firdapse (amifampridine phosphate) and Ruzurgi, with additional development programs in indications such as myasthenia gravis and spinal muscular atrophy type 3.